Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers

References

• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet20053659455 217 22315652604
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet20023609349 1903 191312493255
   PubMed Web of Science ®Google Scholar
• MillsKTBundyJDKellyTNGlobal disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countriesCirculation20161346 441 45027502908
   PubMed Web of Science ®Google Scholar
• cdc.gov [homepage on the Internet]Hypertension Among Adults in the United States: National Health and Nutrition Examination Survey, 2011–2012Centers for Disease Control and Prevention2013 Available from: https://www.cdc.gov/nchs/products/databriefs/db133.htmAccessed November 3, 2017
   Google Scholar
• 100 indicators of Korean Statistical Information Service2015 Available from https://kosis.kr/nsportalStats/nsportalStats_0102Body.jsp;jsessionid=uMBw1xbPFOdNUBjXEBfDU7n9aGSkYXI3m1htNKgAl0AN7qUsg0lJGgobaQp8OyA9.STAT_WAS1_servlet_engine1?menuId=11&NUM=1075Accessed November 28, 2017
   Google Scholar
• KimHSChangKKohYSCYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable anginaCirc Cardiovasc Genet201365 514 52124019397
   PubMed Web of Science ®Google Scholar
• KimHSKimGYYeoCWThe effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjectsBr J Clin Pharmacol2014775 821 83024001154
   PubMed Web of Science ®Google Scholar
• KjeldsenSEJuliusSHypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockersAm Heart J20041485 747 75415523303
   PubMed Web of Science ®Google Scholar
• RosarioBHHendraTJTelmisartan in the treatment of hypertensionExpert Opin Drug Metab Toxicol200844 485 49218433350
   PubMed Web of Science ®Google Scholar
• BenndorfRABogerRHPleiotropic effects of telmisartan: still more to come?J Hypertens2008265 854 85618398324
   PubMed Web of Science ®Google Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet20003559204 637 64510696996
   PubMed Web of Science ®Google Scholar
• NeutelJMFrishmanWHOparilSPapademitriouVGuthrieGComparison of telmisartan with lisinopril in patients with mild-to-moderate hypertensionAm J Ther199963 161 16610423659
   PubMedGoogle Scholar
• KarlbergBELinsLEHermanssonKEfficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study GroupJ Hypertens1999172 293 30210067800
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityHypertension2004435 993 100215007034
   PubMed Web of Science ®Google Scholar
• AbernethyDRThe pharmacokinetic profile of amlodipineAm Heart J19891185 Pt 2 1100 11032530866
   PubMed Web of Science ®Google Scholar
• CarvalhoMOliveiraCHMendesGDSucupiraMMoraesMEDe NucciGAmlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometryBiopharm Drug Dispos2001229 383 39011870677
   PubMed Web of Science ®Google Scholar
• LiuYJiaJLiuGLiSLuCYuCPharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteersClin Ther2009314 777 78319446150
   PubMed Web of Science ®Google Scholar
• ParkJYKimKAParkPWPharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover studyClin Ther20062811 1837 184717213004
   PubMed Web of Science ®Google Scholar
• MeredithPAElliottHLClinical pharmacokinetics of amlodipineClin Pharmacokinet1992221 22 311532771
   PubMed Web of Science ®Google Scholar
• MurdochDHeelRCAmlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular diseaseDrugs1991413 478 5051711448
   PubMed Web of Science ®Google Scholar
• LuksaJJosicDPodobnikBFurlanBKremserMSemi-preparative chromatographic purification of the enantiomers S-(−)-amlodipine and R-(+)-amlodipineJ Chromatogr B Biomed Sci Appl19976932 367 3759210441
   PubMed Web of Science ®Google Scholar
• GoldmannSStoltefussJBornLDetermination of the absolute configuration of the active amlodipine enantiomer as (−)-S: a correctionJ Med Chem19923518 3341 33441388206
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdMajulCROlveraRResults of treatment with telmisartan-amlodipine in hypertensive patientsJ Clin Hypertens (Greenwich)2009114 207 21319614805
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens2007259 1751 176217762635
   PubMed Web of Science ®Google Scholar
• NohYHLimHSKimMJPharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteersClin Ther2012347 1625 163522721873
   PubMed Web of Science ®Google Scholar
• JamesPAOparilSCarterBL2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)JAMA20143115 507 52024352797
   PubMed Web of Science ®Google Scholar
• ManciaGFagardRNarkiewiczK2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2013317 1281 135723817082
   PubMed Web of Science ®Google Scholar
• da SilvaPMEfficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartanClin Drug Investig2010309 625 641
   PubMed Web of Science ®Google Scholar
• ZhangXPLokeKEMitalSChahwalaSHintzeTHParadoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipineJ Cardiovasc Pharmacol2002392 208 21411791006
   PubMed Web of Science ®Google Scholar
• RentschKMThe importance of stereoselective determination of drugs in the clinical laboratoryJ Biochem Biophys Methods2002541–3 1 912543488
   PubMedGoogle Scholar
• DeppeSBogerRHWeissJBenndorfRATelmisartan: a review of its pharmacodynamic and pharmacokinetic propertiesExpert Opin Drug Metab Toxicol201067 863 87120509777
   PubMed Web of Science ®Google Scholar
• YamadaAMaedaKIshiguroNThe impact of pharmacogenet-ics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteersPharmacogenet Genomics2011219 523 53021829131
   PubMed Web of Science ®Google Scholar
• IeiriINishimuraCMaedaKPharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dosePharmacogenet Genomics2011218 495 50521691256
   PubMed Web of Science ®Google Scholar